NRx Pharmaceuticals, Inc.

NASDAQ:NRXP

3.03 (USD) • At close June 14, 2024
Bedrijfsnaam NRx Pharmaceuticals, Inc.
Symbool NRXP
Munteenheid USD
Prijs 3.03
Beurswaarde 32,422,845
Dividendpercentage 0%
52-weken bereik 1.9 - 7.33
Industrie Biotechnology
Sector Healthcare
CEO Mr. Stephen H. Willard Esq.
Website https://www.nrxpharma.com

An error occurred while fetching data.

Over NRx Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the

Vergelijkbare Aandelen

Evelo Biosciences, Inc. logo

Evelo Biosciences, Inc.

EVLO

0.06 USD

Elevation Oncology, Inc. logo

Elevation Oncology, Inc.

ELEV

3.23 USD

Passage Bio, Inc. logo

Passage Bio, Inc.

PASG

1.05 USD

Daré Bioscience, Inc. logo

Daré Bioscience, Inc.

DARE

0.45 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)